• PharmaTher is developing personalized, 3D-printed oral KPV and BPC-157 products for near-term commercialization under a new conditional US compounding pathway.
• The lead products target drug release in the colon, with left-sided ulcerative colitis as the initial focus.
• A previously published 2023 laboratory study demonstrated colon-targeted delivery using budesonide, not the planned peptide products.
• Neither peptide is FDA-approved; both qualify for oral compounding under the policy, subject to conditions including documented human oral bioavailability.
• Commercialization would target healthcare companies, telehealth platforms and pharmacies as partners rather than direct competition for patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmather Holdings Ltd. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.